Chembio Diagnostics, Inc. (CEMI): Price and Financial Metrics

Chembio Diagnostics, Inc. (CEMI): $3.87

-0.02 (-0.51%)

POWR Rating

Component Grades













CEMI Stock Summary

  • CEMI has a market capitalization of $78,307,545 -- more than approximately just 13.5% of US stocks.
  • Over the past twelve months, CEMI has reported earnings growth of 73.58%, putting it ahead of 84.41% of US stocks in our set.
  • Chembio Diagnostics Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -36.02%, greater than the shareholder yield of merely 7.08% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Chembio Diagnostics Inc, a group of peers worth examining would be AMOT, SRI, SRTS, DGII, and VJET.
  • Visit CEMI's SEC page to see the company's official filings. To visit the company's web site, go to

CEMI Stock Price Chart Interactive Chart >

Price chart for CEMI

CEMI Price/Volume Stats

Current price $3.87 52-week high $15.89
Prev. close $3.89 52-week low $3.01
Day low $3.80 Volume 817,800
Day high $4.03 Avg. volume 4,987,953
50-day MA $5.20 Dividend yield N/A
200-day MA $5.09 Market Cap 78.10M

Chembio Diagnostics, Inc. (CEMI) Company Bio

Chembio Diagnostics, Inc., together with its wholly-owned subsidiary, Chembio Diagnostic Systems, Inc., develops, manufactures, markets, and licenses rapid point-of-care (POC) diagnostic tests that detect infectious diseases. The company was founded in 1985 and is based in Medford, New York.

CEMI Latest News Stream

Event/Time News Detail
Loading, please wait...

CEMI Latest Social Stream

Loading social stream, please wait...

View Full CEMI Social Stream

Latest CEMI News From Around the Web

Below are the latest news stories about Chembio Diagnostics Inc that investors may wish to consider to help them evaluate CEMI as an investment opportunity.

If You Had Bought Chembio Diagnostics' (NASDAQ:CEMI) Shares Three Years Ago You Would Be Down 39%

Chembio Diagnostics, Inc. ( NASDAQ:CEMI ) has rebounded strongly over the last week, with the share price soaring 45...

Yahoo | April 7, 2021

Chembio Diagnostics, Nano-X Imaging leads healthcare gainers; Molecular Templates, ACADIA Pharmaceuticals among major losers

Gainers: Chembio Diagnostics (CEMI) +60%, Nano-X Imaging (NNOX) +25%, NanoVibronix (NAOV) +16%, Vivos Therapeutics (VVOS) +15%, Greenwich LifeSciences (GLSI) +14%.Losers: Molecular Templates (MTEM) -26%, ACADIA Pharmaceuticals (ACAD) -17%, Benitec Biopharma (BNTC) -9%, Ikena Oncology (IKNA) -9%, Predictive Oncology (POAI) -6%....

Seeking Alpha | April 5, 2021

ACAD, NNOX, CTRM and DMYD among midday movers

Gainers: Chembio Diagnostics (CEMI) +61%.AeroCentury (ACY) +59%.Xcel Brands (XELB) +54%.dMY Technology (DMYD) +34%.Performant Financial (PFMT) +33%.Nephros (NEPH) +27%.Nano-X Imaging (NNOX) +26%.Regional Health Properties (RHE) +24%.Leaf Group (LEAF) +21%.Bluegreen Vacations (BVH) +19%.Losers: Molecular Templates (MTEM) -26%.Elite Education Group International (EEIQ) -23%.Liberty TripAdvisor (LTRPB) -22%.Castor Maritime (CTRM) -20%.Uxin (UXIN) -19%.ACADIA Pharmaceuticals (ACAD) -17%.Predictive Oncology (POAI) (WBAI) -12%.Canaan (CAN) -12%.P&F Industries (PFIN) -11%....

Seeking Alpha | April 5, 2021

Chembio Diagnostics stock rockets on record volume after commercial launch of rapid COVID-19 test

Shares of Chembio Diagnostics Inc. skyrocketed 63.8% on record volume in afternoon trading Monday, to pace all gainers listed on major U.S. exchanges, in the wake of the point-of-care diagnostics company's announcement of the commercial launch of its rapid COVID-19/flu test. The stock was on track for the biggest one-day percentage gain since it doubled, on March 12, 2004. Trading volume ballooned to 206.6 million shares, compared with the full-day average of less than 1 million shares. The company said its test has been granted emergency use authorization by the Food and Drug Administration. Chembio said after Thursday's closing bell that the product, which produces results in 15 minutes, requires no instrumentation and simultaneously differentiates SARS-CoV-2 antigens and influenza Ty...

Yahoo | April 5, 2021

Chembio Jumps on Launch of Test Distinguishing COVID, Flu

Chembio launched a rapid test, cleared for emergency use by the FDA, that can differentiate between COVID-19 and influenza Type A and Type B.

Yahoo | April 5, 2021

Read More 'CEMI' Stories Here

CEMI Price Returns

1-mo -11.03%
3-mo -34.52%
6-mo -20.21%
1-year -61.65%
3-year -51.01%
5-year -43.91%
YTD -18.53%
2020 4.17%
2019 -19.43%
2018 -30.98%
2017 20.59%
2016 27.58%

Continue Researching CEMI

Want to see what other sources are saying about Chembio Diagnostics Inc's financials and stock price? Try the links below:

Chembio Diagnostics Inc (CEMI) Stock Price | Nasdaq
Chembio Diagnostics Inc (CEMI) Stock Quote, History and News - Yahoo Finance
Chembio Diagnostics Inc (CEMI) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9212 seconds.